We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cordless Handheld Device Uses Vibrations to Eliminate Fingerstick Pain for Blood Sugar Testing

By LabMedica International staff writers
Posted on 10 Nov 2021
Print article
Image: DigiVibe Glucose Monitoring Device (Photo courtesy of BING Innovations, LLC)
Image: DigiVibe Glucose Monitoring Device (Photo courtesy of BING Innovations, LLC)

A new portable tool uses innovative vibration technology to improve the ease of diabetes management.

BING Innovations, LLC (Boca Raton, FL, USA) has launched DigiVibe, a cordless handheld device that uses vibrations to eliminate the pain of getting the finger pricked. Specifically designed for blood glucose monitoring, DigiVibe applies vibration directly to the finger, blocking pain signals to the brain and helping to make the process more tolerable for both children and adults.

While many people only get their finger-pricked at their annual checkup, for those with diabetes, glucose monitoring means having to prick their finger three or more times each day. DigiVibe, an FDA-registered and CE-certified device, has been created to reduce the pain and anxiety of checking glucose levels, whether a person is not keen on needles or just weary of repeated finger pricks. The easy-to-use and portable device adheres to any flat surface for hands-free use, making self-testing and diabetes management easier and more convenient than ever before. For a doctor who regularly deals with diabetic patients or an individual who must test their glucose levels regularly, the DigiVibe device can make the process easier and virtually painless - in as little as 12 seconds.

The DigiVibe Starter Kit includes a sleek carrying case containing one DigiVibe device, stand and tip, lancing device, five 30-gauge lancets, and one AA lithium battery. The battery is designed to last for approximately three months or roughly 450 finger sticks for a single user. Plus, there is enough space in the carrying case to fit one’s regular test strips and glucose testing device. Additional accessories or refills of supplies can also be ordered anytime on the DigiVibe website. One-time use disposable tips and lancing devices are also available for medical practitioners.

"The conventional way to test blood sugar for diabetes is often associated with pain, discomfort, and even fear, but DigiVibe has set out to dramatically make this experience better," said Dr. Marcelo Bendix, Endocrinologist and DigiVibe Medical Advisor. "Pain and finger soreness are among the top reasons diabetics sometimes skip blood glucose testing, which is not only dangerous, but makes it quite difficult for them to effectively manage diabetes. DigiVibe is truly a game-changer; it will allow patients to stay on top of their glucose testing and no longer fear the dreaded finger-prick they have to endure in the doctor's office and at home."

Related Links:
BING Innovations, LLC 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.